NCT06445322 Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
| NCT ID | NCT06445322 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ascidian Therapeutics, Inc |
| Condition | Stargardt Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-06-20 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-06-20 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.
Eligibility Criteria
Key Inclusion Criteria: * Presence of mutations in the ABCA4 gene * ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy) Key Exclusion Criteria: * The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy * Retinal disease other than ABCA4-related retinopathy * Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.
Contact & Investigator
Alia Rashid
STUDY DIRECTOR
Ascidian Therapeutics
Frequently Asked Questions
Who can join the NCT06445322 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, studying Stargardt Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06445322 currently recruiting?
Yes, NCT06445322 is actively recruiting participants. Contact the research team at researchtrials@ascidian-tx.com for enrollment information.
Where is the NCT06445322 trial being conducted?
This trial is being conducted at San Francisco, United States, Gainesville, United States, Baltimore, United States, Boston, United States and 4 additional locations.
Who is sponsoring the NCT06445322 clinical trial?
NCT06445322 is sponsored by Ascidian Therapeutics, Inc. The principal investigator is Alia Rashid at Ascidian Therapeutics. The trial plans to enroll 50 participants.